Research analysts covering Haoxi Health Technology.
Recent press releases and 8-K filings for HAO.
Haoxi Health Technology Ltd Enters At-The-Market Issuance Sales Agreement
HAO
- Haoxi Health Technology Limited entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp. on January 23, 2026, to offer and sell Class A Ordinary Shares.
- The company may sell up to $80,000,000 in Class A Ordinary Shares through this program.
- Aegis Capital Corp. will act as the sales agent, receiving a commission of 2.5% of the aggregate gross proceeds from each sale, and will be reimbursed for certain expenses up to $75,000 annually.
Jan 23, 2026, 10:19 PM
Haoxi Health Technology Completes $5 Million Private Placement
HAO
- Haoxi Health Technology Limited completed a private placement on December 3, 2025, issuing 6,250,000 Class A ordinary shares and 12,500,000 warrants, which generated $5 million in gross proceeds.
- The net proceeds from this offering will be used for working capital and general corporate purposes.
- The warrants have an initial exercise price of $0.80 per share, with a floor price of $0.20 per share, and are exercisable for five years from the Initial Exercise Date of December 3, 2025.
- The warrant exercise price is subject to adjustment on the seventh calendar day after issuance to 22% of the "Minimum Price".
Dec 3, 2025, 10:00 PM
Haoxi Health Technology Ltd to Hold Extraordinary Meeting on Share Consolidation and Voting Power Changes
HAO
Delisting/Listing Issues
Proxy Vote Outcomes
Accounting Changes
- Haoxi Health Technology Ltd (HAO) will hold an Extraordinary Meeting of Shareholders on December 8, 2025, to vote on several proposals, with the record date for voting set as November 7, 2025.
- One key proposal (No. 1) seeks to increase the voting rights attached to Class B ordinary shares from ten (10) votes to thirty (30) votes per share. If approved, this change would increase CEO Zhen Fan's total voting power from 47.94% to 73.42%.
- Another significant proposal (No. 4) is a share consolidation (reverse stock split) at a ratio of no less than two-for-one (2:1) and no more than one-hundred-and-fifty-for-one (150:1), to be implemented prior to November 15, 2026. This measure is aimed at helping the company maintain compliance with Nasdaq's minimum bid price requirement and improving the marketability and liquidity of its Class A Ordinary Shares.
- The company also proposes to increase its authorized share capital from USD1,000,000 to USD3,250,000 (Proposal No. 2) and further to up to a maximum of USD450,250,000 (Proposal No. 5), conditional upon the share consolidation taking effect.
Nov 12, 2025, 9:15 PM
Haoxi Health Technology Limited enters into private placement agreement
HAO
Private Placement
Equity Offering
- On October 13, 2025, Haoxi Health Technology Limited entered into a securities purchase agreement for a private placement.
- The company agreed to sell an aggregate of 5,217,391 Class A ordinary shares for an approximate aggregate purchase price of $1.2 million.
- The net proceeds from this offering will be used for working capital and general corporate purposes ,.
Oct 17, 2025, 9:25 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more